ProBio – Biologics CDMO

ProBio, a subsidiary of GenScript Biotech Corporation, offers end-to-end CDMO services from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in CGT, antibody and recombinant protein drug, aiming to accelerate drug development for customers. ProBio has established companies in the United States, the Netherlands, South Korea, and China (Hong Kong, Shanghai, and Nanjing) and other regions to serve global customers, and has helped customers in the United States, Europe, Asia Pacific and other regions obtain more than 130 IND approvals since October 2017.

ProBio’s total CGT solution covers CMC of plasmid, viral vector, mRNA vaccine and nucleic acid drugs for IND filing as well as clinical manufacturing and commercial manufacturing. ProBio integrated CMC solution for plasmid and viral vector including cell banking, process development, characterization and validation, analytical method development and validation, and stability study to enable cell and gene therapy go to next milestone.

ProBio’s innovative solutions for biologics discovery and development include therapeutic antibody discovery, antibody engineering and in vitro/ in vivo pharmacology studies. In the biologics CDMO service, ProBio has built a DNA to GMP material platform, including stable cell line development, host cell commercial license, process development, analytical development to clinical and commercial manufacturing, and offer fed-batch and perfusion processes to meet the growing needs for antibody and protein drugs. ProBio has established GMP capacity that meets regulatory requirements of the US Food and Drug Administration (FDA), European Medicines Agency (EMA) and National Medical Products Administration (NMPA).

Toward the mission of “Innovation through Collaboration”, ProBio is committed to helping customers shorten the timeline for the development of biological drugs from discovery to commercialization, significantly lowering R&D costs and shaping a healthier future.